This is a snippet of the transcript.Contact Salesto get full access.
Typically, yes. In top 20 pharma, there's good penetration for QualityDocs, but it's higher for QMS now. This is because, even with fewer users in QMS than in QualityDocs, most top 20 pharma companies might not love their document management but find it compliant enough. However, QMS involves high-risk items like deviations, CAPAs, and change controls, which are higher compliance risks. That's why more top 20 companies prioritize replacing QMS first, as it poses greater compliance concerns compared to Document Management.
This is a snippet of the transcript.Contact Salesto get full access.
I would say the win rate for documents and QMS among the top 20 is actually very high. It is rare for Veeva to lose there. If they do, it's usually because the client wants the software to fit their needs, not the other way around, which is uncommon since the industry trend is to standardize processes. Companies are encouraged to align with industry standards rather than being unique.
This is a snippet of the transcript.Contact Salesto get full access.
Those five are the core elements of QMS: deviation, CAPA, change control, audit, supplier quality. Complaints depends how customers choose to do it because they have other systems and outsource a lot of the intake for that, but complaints may also be in that list. Once those boxes are checked, they usually say let's take a break from QMS and look at the Document Management side to bring that in.
This is a snippet of the transcript.Contact Salesto get full access.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.